AIM: To investigate the effect of intravitreal ranibizumab(IVR)in the treatment of exudative age-related macular degeneration(AMD)with serous retinal pigment epithelium detachment(SPED)in elderly patients.

METHODS: We Selected 60 elderly patients(60 eyes)with AMD and SPED in our hospital from February 2015 to February 2016, treated by intravitreal injection of ranibizumab. The best corrected visual acuity(BCVA), PED height and volume, central fovea thickness(CFT)and aqueous humor vascular endothelial growth factor(VEGF)were measured before and after treatment.

RESULTS: The BCVA of patients with after treatment for 1, 3 and 6mo were 0.6±0.1, 0.4±0.1 and 0.3 ±0.1, and were significantly higher than those before treatment(P<0.05). At 1, 3 and 6mo after treatment PED height and volume were significantly lower than before treatment(P<0.05), of which 6mo after the treatment PED height and volume were 240.02±35.10μm and 0.310±0.120mm³. At 6mo after treatment CFT was 290.02±33.10μm, significantly lower than before and 1mo after treatment(P<0.05). At 1, 3 and 6mo after treatment VEGF were lower than those before treatment(P<0.05), in which 6mo after the treatment aqueous humor VEGF was 149.11±28.89pg/mL. No endophthalmitis, uveitis and so on adverse reactions were observed during treatment.

CONCLUSION: IVR has a good effect in the treatment of exudative AMD in elderly patients with serous PED, which can effectively improve the visual acuity of patients, reduce the height and volume of PED and the concentration of VEGF in aqueous humor, and it is safe and reliable.